pharma · Bladder (Urothelial, Transitional Cell) Cancer · Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) · RLMD
RELMADA THERAPEUTICS
RELMADA THERAPEUTICS, INC.
RELMADA THERAPEUTICS is a pharma organization headquartered in Coral Gables, USA. It trades on NYSE under ticker RLMD. Primary therapeutic focus areas include Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urot
Company details
- Status
- Public
- HQ
- Coral Gables, USA
- Founded
- 2004
- Employees
- 33
- Programs
- 6
- Drugs
- 5
- Patents
- 7
REL-1017
Phase 3 · small molecule · Major Depressive Disorder
REL-1017 for Major Depressive Disorder is a Phase 3 program (small_molecule) at RELMADA THERAPEUTICS, INC. with 3 ClinicalTrials.gov record(s).
Internal code REL-1017-310
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- RELMADA THERAPEUTICS, INC.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Major Depressive Disorder
- Status
- completed
- Trials
- 3